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Abstract: Pathological gait is often associated with a lack of symmetry. A possible way to quantify
this feature is to use acceleration data measured by a sensor located on the lower trunk. The most
common approach calculates a symmetry index starting from the autocorrelation function, aiming
to measure the divergence in motion of the left and right sides of the body. The various methods
proposed to implement this approach are based on nonlinear and discontinuous functions, and the
interpretation of their output is far from straightforward. The aim of this study was to propose a
linear and easier to interpret quantification measure for gait asymmetry. The proposed measure
was tested on data from healthy controls and from patients with Multiple Sclerosis and Parkinson’s
Disease, and it was shown to negate the flaws present in previous methods and to provide more
directly interpretable results.
Keywords: asymmetry; gait; accelerometer; IMU
1. Introduction
Pathological gait is often associated with a lack of symmetry [1]. Asymmetric gait
is less efficient, increases oxygen consumption, and the energy cost of locomotion may
lead to loss of bone mass density, osteoarthritis, and musculoskeletal injury [1]. A widely
applied approach to quantify asymmetric gait relies on the calculation of autocorrelation
from accelerometer data [2,3]. This approach is based on calculations of regularity, which
refers to the similarity between consecutive strides or steps. Regularity and symmetry are
two metrics that have the potential to explain the quality of gait. These metrics have been
shown to carry additional information compared to measures of spatiotemporal symmetry
when investigating pathological gait [4]. Recently, regularity and symmetry have been
suggested to be potential biomarkers for quantifying gait disability in ageing and diseases,
including multiple sclerosis (MS) and Parkinson’s disease (PD) [3–5].
Regularity is determined by applying the following unbiased autocorrelation proce-








where xi (i = 1, 2, . . . , N) are timeseries and m is the lag parameter, which is the phase shift
in number of samples. Starting from Equation (1), step (Ad1) and stride (Ad2) regularity
are defined as the first two peaks of the correlation between the acceleration signal and
the acceleration signal phase-shifted to the average step and stride time (Figure 1). These
phase shifts are consistent with the first and second dominant periods of the unbiased
autocorrelation curve, respectively. Ad1 and Ad2 can vary between −1 and 1, with 0
indicating maximum irregularity. When considering lower trunk accelerations, negative
values of Ad1 are typically recorded in the medio-lateral (ML) direction as a result of the
alternating lower limb motions, while mostly positive values are observed in the anterior-
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posterior (AP) and vertical (V) directions. Positive values of Ad2 are most likely to be
observed in all movement directions.
−
− S = Step regularityStride regularity = AdAd  
AS = |Ad − Ad |Mean Ad , Ad
− −
−
Figure 1. (a) Lower back acceleration signal of one participant walking up and down a 10 m walkway; (b) Acceleration
signal for one pass taken from the signal as displayed in panel a. (c) Step (Ad1) and stride (Ad2) regularity are defined as
the first two peaks of the unbiased autocorrelation coefficient, respectively.
Moe-Nilssen and Helbostad [3] initially proposed to calculate gait symmetry as a ratio
between step and stride regularity (Equation (2)). In this definition, perfect theoretical
symmetry is achieved when step regularity is equal to the stride regularity, i.e., SMN = 1 in
AP and V direction and when SMN = 1 in the ML direction. Values lower or greater than








Later, Kobsar et al. [2] suggested quantifying gait symmetry using the ratio be-
tween the absolute difference between Ad1 and Ad2 and the average of Ad1 and Ad2
(Equation (3)) in order to focus on the actual difference between steps and strides regularity
rather than only on their ratio. With this definition, quantifying asymmetry rather than
symmetry, greater values indicate a higher degree of asymmetry between the left and






In practice, for both Equations (2) and (3), the value of symmetry tends to infinity as
the denominator approaches zero. This generates a non-linear scale and adds complexity
to the interpretation of the calculated values. Furthermore, the function surfaces for both
ASK and SMN are discontinuous (Figure 2a,b). This latter point is particularly critical for
ASK: for two participants with a very similar Ad1 (e.g., −0.71 vs. −0.69) and identical
Ad2 (e.g., 0.7), the asymmetry calculation might result in very different values (e.g., −282
and 278 for ASK in this example). Overall, both definitions of symmetry hinder clinical
interpretation of the data and comparison of different outcomes both between and within
participants. The aim of this paper is therefore to propose a linear definition of symmetry,
illustrating how this can overcome the above discussed issues, leading to results that would
be easier to interpret when adopted in a clinical context.
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Figure 2. (a) Function surface of symmetry based on the formula of Moe-Nilssen and Helbostad [3]; (b) Function surface of
asymmetry based on the formula of Kobsar et al. [2]. (c) Function surface of asymmetry based on the formula proposed in
this article. For the sake of allowing visual representation, all function domains were limited varying Ad1 and Ad2 between
−1 and 1 at 0.01 intervals.
2. Materials and Methods
To tackle the issues of nonlinearity and discontinuity in the previous equations, we












Equation (4) provides a linear scale, ranging between −1 and 1 and where AS = 0
indicates perfect gait symmetry (Figure 2c), irrespective of the direction of motion under
investigation. Further, while positive symmetry values relate to a gait pattern with a higher
regularity of strides compared with steps, negative symmetry values correspond to a gait
pattern where the strides are more irregular than the steps. This brings in additional clinical
relevance with respect to previous propositions.
In order to investigate the behavior of the three functions when applied to real data,
three available datasets were retrospectively analysed (Supplementary Materials). These
included data collected from three participant groups within different studies carried out at
the Sheffield Teaching Hospitals (which had all received ethical approval from the relevant
boards): 24 healthy controls (HC), 20 individuals with Parkinson’s Disease (PD), and
20 individuals with multiple sclerosis (MS). These two neurological progressive diseases
were chosen for having different aetiologies which reflect in a variety of different clinical
symptoms and, from a mobility perspective, in differently impaired gait patterns. The
clinical characteristics of the patients within the two cohorts were also quite heterogeneous,
as described in Table 1.
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Table 1. Participant Characteristics.
Characteristic 24 HC 20 PD 20 MS
Sex
8 males 14 males 14 males
16 females 6 females 6 females
Age (mean ± SD) 50 ± 8 years 59 ± 7 years * 45 ± 14 years
Disease characteristics
N/A Average UPDRS-III: 33 ± 9 Average EDSS: 3.7 ± 1.6
Mild: 9 participants Mild: 6 participants
Moderate: 11 participants Moderate: 3 participants
Severe: 0 participants Severe: 11 participants
HC: Healthy controls; PD: participants with Parkinson’s disease; MS: participants with multiple sclerosis. * Significant difference compared
to healthy controls and patients with MS based on a one-way ANOVA. Post-hoc tests were performed with a Bonferroni correction
to compare the different groups. Disease characteristics were defined as Mild: UPDRS-III ≤ 32, Moderate: 33 ≤ UPDRS-III ≤ 58,
Severe: UPDRS-III ≥ 59 [6] for PD and Mild: EDSS ≤ 2, Moderate: 2.5 ≤ EDSS ≤ 3.5, Severe: EDSS ≥ 4 [7].
The data from the MS cohort used in this study is a subset of the data described in
Angelini et al. [8]. Twenty participants were selected from that study among those not
using walking aids, ensuring that they were sex-matched to the PD cohort. Participants
performed a 6-min walk test by walking back and forth on a 10 m walkway in a hospital
corridor at a comfortable speed while wearing triaxial inertial measurement units (IMUs)
(OPAL, APDM Inc., Portland, OR, USA, 128 Hz). One sensor was placed on the lower back,
overlying the fifth lumbar vertebra, with a velcro strap, and two sensors were attached
to the left and right shin at the level of the ankle, respectively. The accelerations were
reoriented to a horizontal-vertical coordinate system and filtered with a 10 Hz cut-off,
zero phase, low-pass Butterworth filter. Turning phases were identified and isolated using
the angular velocity signals [8], so that steady state walking passes could be identified
(Figure 1). To be able to compare the same amount of walking passes for each group,
the quantity of walking passes completed was defined for each group (HC: 824 passes;
MS: 519 passes; PD: 128 passes). The number of passes included was standardized to 128
by taking every 4th pass for MS and every 6th pass for HC. For each of the walking passes
Ad1 and Ad2 were calculated as the first two peaks in the autocorrelation function for signal
recorded in the V, ML, and AP directions and then used to calculate AS, SMN, and ASK.
Normality assumption was checked with the Shapiro-Wilk test and QQ-plots. Since
most of the data was not normally distributed, a nonparametric test (Independent-Samples
Kruskal-Wallis Test) was used to compare the participant groups. Separate tests were
performed for the different metrics (Ad1, Ad2, SMN, ASK, AS) for each axis (AP, ML, V).
Pairwise comparisons adjusted by the Bonferroni correction were used as post hoc tests to
identify where specific differences occurred between the cohorts. The level of significance
was set at 0.05. Calculations were performed using SPSS, version 26 (SPSS; Inc, Chicago,





where z is the z-score based on the pairwise comparisons, and N is the number of total
observations on which z is based. Thresholds of 0.1, 0.3, and 0.5 were recommended by
Cohen [9] for small, medium, and large effect sizes, respectively.
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3. Results
Figure 3 shows the comparison between the three different patient groups for different
outcome variables (Ad1, Ad2, SMN, ASK, AS) in the three directions of motion. Table 2
shows the significant differences with accompanying effect sizes for the group comparisons.
In the results below, values will be reported as Median [Q1, Q3], where Q1 is the first
quartile and Q3 is the third quartile. As immediately visible in the figure, the ASK values
covered a very broad range of values, especially in the ML direction, where values up to
1000 were observed. This reflected into a substantially different interpretation of the data
with respect to both SMN and AS when statistically comparing the three different groups.
In the AP direction, lower regularity was observed for both steps and strides in
both MS (Ad1: 0.81 [0.65, 0.88]; Ad2: 0.86 [0.75, 0.92]) and PD (Ad1: 0.82 [0.74, 0.88];
Ad2: 0.89 [0.83, 0.92]) compared to the HC (Ad1: 0.88 [0.84, 0.91]; Ad2: 0.92 [0.89, 0.94])
(Figure 3), with no significant differences between the two patient groups. Slightly less
asymmetric gait was observed for the HC according to AS (HC: 0.01 [0.00, 0.04], MS: 0.02
[0.01, 0.06], PD: 0.02 [0.00, 0.05]), but these differences were not significant (Kruskal-
Wallis p = 0.054). According to SMN, the MS had lower symmetry than the HC (HC: 0.97
[0.92, 1.00], MS: 0.95 [0.85, 0.98], PD: 0.95 [0.87, 1.00]). The ASK values suggested much
higher asymmetry for the PD and MS group than for the HC cohort (HC: 0.04 [0.02, 0.09],
MS: 0.06 [0.03, 0.17], PD: 0.06 [0.03, 0.13]). Again, no significant difference was found
between the patient cohorts.
In the ML direction, significant differences were found between the three groups for
step and stride regularity, with HC having the most regular steps (Ad1: −0.79 [−0.85, 0.68])
and strides (Ad2: 0.86 [0.81, 0.90]). Compared to PD, MS patients had fewer regular steps
(Ad1, MS: −0.57 [−0.76, −0.54] vs PD: −0.70 [−0.80, −0.54]) and strides (Ad2, MS: 0.75
[0.58, 0.84] vs PD: 0.82 [0.71, 0.87]). For gait symmetry, SMN values suggested higher
symmetry for the HC, but no significant differences were found between the three groups
(HC: −0.93 [−0.98, −0.76]; MS: −0.90 [−1.00, −0.70]; PD: −0.89 [−0.97, −0.76], Kruskal-
Wallis: p = 0.119). ASK values had a much larger range in the ML direction than in AP
or V and as a result indicated that the HC had a much higher level of asymmetry (34.10
[13.55, 100.84]) than both PD (17.24 [5.59, 44.35]) and MS patients (11.20 [3.96, 38.94]),
but the differences between the latter two groups remained non-significant due to the
excessively large variability within the groups. The AS value indicated no significant
differences between the three cohorts (HC: 0.05 [0.01, 0.10]; MS: 0.04 [0.00, 0.10]; PD: 0.05
[0.01, 0.10], Kruskal-Wallis: p = 0.152).
In the V direction, both MS (Ad1: 0.85 [0.73, 0.93]) and PD (Ad1: 0.89 [0.82, 0.92]) had
significantly lower step regularity compared to HC (Ad1: 0.94 [0.90, 0.96]), but no significant
differences were observed between the two patient groups. Significant differences were
found between the three groups for stride regularity, with HC (Ad2: 0.96 [0.93, 0.97])
having the most regular strides, followed by PD (Ad2: 0.93 [0.90, 0.96]) and MS (Ad2: 0.90
[0.77, 0.95]). When symmetry was calculated by SMN, the PD cohort (SMN: 0.96 [0.88, 1.00])
appeared to be less symmetrical than the HC (SMN: 0.99 [0.96, 1.00]) and the MS cohorts
(SMN: 0.98 [0.93, 1.01]). Meanwhile, ASK values indicated that there were differences
between HC (0.02 [0.01, 0.04]) and both MS (0.04 [0.02, 0.10]) and PD (0.05 [0.02, 0.13]),
but not between the two patient groups. AS values were closer to the SMN findings and
significant differences between cohorts were also observed (Kruskall Wallis p < 0.001)
with HC (AS: 0.01 [0.00, 0.02]) having lower values than MS (AS: 0.01 [0.00, 0.02]) and PD
(AS: 0.02 [0.00, 0.05]).
Symmetry 2021, 13, 1560 6 of 9
− − − −
− − −
− − − −
Figure 3. Comparison between the three different patient groups for different outcome variables (Ad1, Ad2, AS, SMN, ASK).
*: significant difference between groups. Ad1: step regularity; Ad2: stride regularity; AS: Asymmetry as proposed in this
article; SMN: symmetry as proposed by Moe-Nilssen and Helbostad [3]; ASK: Asymmetry as proposed by Kobsar et al. [2];
AP: anterior-posterior direction; ML: medial-lateral direction; V: vertical direction.
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Table 2. p-values and effect sizes for comparisons between groups.
Direction Comparison Ad1 Ad2 AS SMN ASK
AP Group p < 0.001 * p < 0.001 * p = 0.054 p = 0.022 * p = 0.002 *
HC-MS p < 0.001 * p < 0.001 na p = 0.023 p = 0.006
r = −0.30 (m) r = −0.31 (m) r = −0.14 (s) r = −0.16 (s)
HC-PD p < 0.001 * p < 0.001 na p = 0.138 p = 0.009
r = −0.27 (s) r = 0.23 (s) r = −0.10 (s) r = −0.15 (s)
MS-PD p = 1.000 p = 0.371 na p = 1.000 p = 1.000
r = −0.02 r = −0.08 r = −0.03 r = −0.01
ML Group p < 0.001 * p < 0.001 * p = 0.152 p = 0.119 p < 0.001 *
HC-MS p < 0.001 * p < 0.001
na na
p < 0.001
r = −0.33 (m) r = −0.35 (m) r = −0.23 (s)
HC-PD p < 0.001 * p = 0.001
na na
p = 0.005
r = −0.20 (s) r = −0.19 (s) r = −0.16 (s)
MS-PD p = 0.048 * p = 0.003
na na
p = 0.588
r = −0.12 (s) r = −0.17 r = −0.07
V Group p < 0.001 * p < 0.001 * p = 0.001 * p = 0.001 * p < 0.001 *
HC-MS p < 0.001 * p < 0.001 p = 0.849 p = 0.675 p < 0.001
r = −0.40 (m) r = −0.40 (m) r= −0.05 r = −0.06 r= −0.23 (s)
HC-PD p < 0.001 * p < 0.001 p = 0.001 p = 0.001 p < 0.001
r = −0.36 (m) r = −0.23 (s) r = −0.19 (s) r = −0.19 (s) r= −0.26 (s)
MS-PD p = 1.000 p = 0.003 p = 0.025 p = 0.037 p = 1.000
r = −0.04 r = −0.17 (s) r = −0.13 (s) r = −0.13 (s) r= −0.04
Ad1: step regularity; Ad2: stride regularity; AS: Asymmetry as proposed in this article; SMN: symmetry as proposed by Moe-Nilssen and
Helbostad [3]; ASK: Asymmetry as proposed by Kobsar et al. [2]; AP: anterior-posterior direction; ML: medial-lateral direction; V: vertical
direction; p = p-value, * significant difference (p < 0.05); r: effect size; (s): small effect size, (m): moderate effect size; (l): large effect size;
na= not applicable, due to no significant effect for the Independent-Samples Kruskal-Wallis Test.
4. Discussion
The aim of this paper was to propose a linear and easy to interpret quantification
of gait asymmetry and illustrate how this new calculation could facilitate the compari-
son between observations related to the different directions of motion and the clinical
interpretation of the data. Previous quantifications of gait (a)symmetry, SMN and ASK,
implement discontinuous scales potentially ranging to infinity which hinders interpretation
of results. The proposed asymmetry metric, conversely, is a continuous and linear scale
varying between −1 and 1, with only one value (AS = 0) indicating perfect symmetry. In
this way it is possible to obtain measures of gait asymmetry that are immediately com-
parable. In addition, the proposed scale allows the immediate identification of whether
asymmetries originate from differences in step or stride regularity. All these aspects make
highlighting and interpreting differences between the gait patterns of different participants
more straightforward.
One of the main complexities of previous definitions was associated with their appli-
cation to the analysis of the data measured in the ML direction. In this direction, negative
values of Ad1, would contribute to negative values of both SMN and ASK, which would
eventually cause discontinuity in their values. To compensate for this issue, even if not
explicitly stated in their paper, it might be assumed from the reported results that in Kob-
sar et al. [2], Ad1 was included as an absolute value in the calculation of ASK in the ML
direction. This would explain the large differences between the values reported here and
those observed for their young (15.34 ± 18.52) and older (15.42 ± 19.61) participants. The
same would apply to the results of Barden et al. [10], who reported positive values for Ad1,
both for healthy controls and patients with knee osteoarthritis. As confirmed by the author,
Angelini et al. [8], took the absolute value of Ad1 in the ML direction when calculating
ASK and then plotted the inverse values to facilitate comparison with the other directions.
Our proposed calculation contains an explicit reference to the different calculation for the
different directions and will hence allow for more straightforward comparisons between
results in future studies.
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To investigate the effects that different calculations would have on the clinical inter-
pretation of the data, we tested the behavior of the various methods in discriminating
between three patient groups. While consistent results were observed in all directions
when calculating symmetry using SMN and AS, ASK indicated a different interpretation. In
particular, ASK provided a much larger range of values calculated for AS. There were also
large disparities between data from different signal axes, with ranges of values in the ML
direction being up to 1000 times bigger than those in the AP and V directions. This would
make it virtually impossible to compare results from individual patients. Despite its consis-
tency with AS in terms of between groups comparison, the complexity of interpretation of
non-linear data still needs to be considered for SMN.
In the present study, we were able to show the analytical flows of current methods and
highlight the risks of data misinterpretation that could stem from a lack of consistency of
the results obtained from the various calculations. In line with previous literature (Angelini
et al. [5]; Buckley et al. [4]), our results indicate that while step and stride regularity have
a clear potential as biomarkers of disease progression in MS and PD, step asymmetry
seems to be less relevant for these patients. While it might be hypothesized that the
proposed index could be sensitive to gait impairments when investigating cohorts with
highly asymmetric walking, such as for example hemiplegic patients or those who had a
hip replacement, additional investigations would be needed to prove this hypothesis.
This study has its clear limitations. First of all, as the size of the cohorts were limited
and the two groups were highly heterogeneous, generalisability and clinical interpretability
of the findings are also limited. Also, this hinders the possibility of establishing a clear
cause-effect relationship with respect to disease progression. More importantly, a full
validation of the clinical meaning of the index would require data to be simultaneously
collected with a gold standard such as an optoelectronic system. This would allow further
investigatation of the link between specific impairments and motion, and evaluation of its
sensitivity to change.
5. Conclusions
This study proposed a linear index for the quantification of gait symmetry and illus-
trated how this overcomes the limitation of previous definitions. The new index provides
comparable and interpretable data in all directions of motion.
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